

### Supplemental references

- S1. Czaja, A.J., and Carpenter, H.A. 2004. Decreased fibrosis during corticosteroid therapy of autoimmune hepatitis. *J. Hepatol.* **40**:646–652.
- S2. Kweon, Y.O., et al. 2001. Decreasing fibrogenesis: an immunohistochemical study of paired liver biopsies following lamivudine therapy for chronic hepatitis B. *J. Hepatol.* **35**:749–755.
- S3. Iredale, J.P. 2001. Hepatic stellate cell behavior during resolution of liver injury. *Semin. Liver. Dis.* **21**:427–436.
- S4. Poynard, T., et al. 2002. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. *Gastroenterology.* **122**:1303–1313.
- S5. Ahmed, A., and Keeffe, E.B. 2001. Hepatitis C virus and liver transplantation. *Clin Liver Dis.* **5**:1073–1090.
- S6. Charlton, M. 2003. Natural history of hepatitis C and outcomes following liver transplantation. *Clin. Liver. Dis.* **7**:585–602.
- S7. Tome, S., and Lucey, M.R. 2004. Review article: current management of alcoholic liver disease. *Aliment Pharmacol. Ther.* **19**:707–714.
- S8. Lieber, C.S. 1997. Role of oxidative stress and antioxidant therapy in alcoholic and nonalcoholic liver diseases. *Adv. Pharmacol.* **38**:601–628.
- S9. Harrison, S.A., Torgerson, S., Hayashi, P., Ward, J., and Schenker, S. 2003. Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis. *Am. J. Gastroenterol.* **98**:2485–2490.
- S10. Ueki, T., et al. 1999. Hepatocyte growth factor gene therapy of liver cirrhosis in rats. *Nat. Med.* **5**:226–230.
- S11. Bustos, M., et al. 2003. Protection against liver damage by cardiotrophin-1: a hepatocyte survival factor up-regulated in the regenerating liver in rats. *Gastroenterology.* **125**:192–201.
- S12. Tomita, K., et al. 2004. Pioglitazone prevents alcohol-induced fatty liver in rats through up-regulation of c-Met. *Gastroenterology.* **126**:873–885.
- S13. Neuschwander-Tetri, B.A., Brunt, E.M., Wehmeier, K.R., Oliver, D., and Bacon, B.R. 2003. Improved nonalcoholic steatohepatitis after 48 weeks of

treatment with the PPAR-gamma ligand rosiglitazone. *Hepatology*. **38**:1008–1017.

S14. Brenner, B.M., et al. 2001. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. *N. Engl. J. Med.* **345**:861–869.

S15. Yokohama, S., et al. 2004. Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis. *Hepatology*. **40**:1222–1225.

S16. Rimola, A., et al. 2003. Beneficial effects of drugs interfering with the renin-angiotensin system on the development of fibrosis in hepatitis C recurrence after liver transplantation. *Am. J. Transplan.* **5**:433.

S17. Shimizu, I. 2000. Sho-saiko-to: Japanese herbal medicine for protection against hepatic fibrosis and carcinoma. *J. Gastroenterol. Hepatol.* **15**(Suppl.):D84–D90.

S18. Fang, B., et al. 2004. Systemic infusion of FLK1(+) mesenchymal stem cells ameliorate carbon tetrachloride-induced liver fibrosis in mice. *Transplantation*. **78**:83–88.

S19. Kollet, O., et al. 2003. HGF, SDF-1, and MMP-9 are involved in stress-induced human CD34<sup>+</sup> stem cell recruitment to the liver. *J. Clin. Invest.* **112**:160–169. doi:10.1172/JCI200317902.

S20. Beljaars, L., et al. 2000. Successful targeting to rat hepatic stellate cells using albumin modified with cyclic peptides that recognize the collagen type VI receptor. *J. Biol. Chem.* **275**:12743–12751.

S21. Fried, M.W., et al. 2002. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. *N. Engl. J. Med.* **347**:975–982.

S22. Baroni, G.S., et al. 1996. Interferon gamma decreases hepatic stellate cell activation and extracellular matrix deposition in rat liver fibrosis. *Hepatology*. **23**:1189–1199.

S23. Lonardo, A., et al. 2004. Steatosis and hepatitis C virus: mechanisms and significance for hepatic and extrahepatic disease. *Gastroenterology*. **126**:586–597.

S24. Lieber, C.S. 2004. New concepts of the pathogenesis of alcoholic

liver disease lead to novel treatments. *Curr. Gastroenterol. Rep.* **6**:60–65.

S25. Dufour, J.F., DeLellis, R., and Kaplan, M.M. 1997. Reversibility of hepatic fibrosis in autoimmune hepatitis. *Ann. Intern. Med.* **127**:981–985.

S26. Mitchell, S.A., et al. 2001. A preliminary trial of high-dose ursodeoxycholic acid in primary sclerosing cholangitis. *Gastroenterology.* **121**:900–907.

S27. Promrat, K., et al. 2004. A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. *Hepatology.* **39**:188–196.

S28. Friedman, S.L., and Arthur, M.J. 2002. Reversing hepatic fibrosis. *Sci. Med.* **8**:194–205.